Taro Holding Sun Back In The Short Term

BMI View: Drugmakers based in emerging markets will expand their presence in developed countries. Firms in developing countries enjoy low operating costs but have historically lacked the capital to venture into international expansion. As economies in these non-traditional markets grow, capital will be released for investment in the development of production capabilities and marketing operations, with output destined for domestic and international

To read the full article, please choose one of the following options: